“Teething Problems” Seen with FMD Implementation: No Shortages but Much Confusion
This article was originally published in The Gold Sheet
There are “teething problems” in the implementation of the active substance import provisions of FMD, said one EU industry representative while another official called things “a mess” as member states and industry work to sort things out - but the feared drug shortages have not materialized as major API producing countries have ramped up at the last minute and are producing the written declarations attesting that their APIs meet EU GMP requirements.
You may also be interested in...
Technologies like head-mounted tablets became critical for method transfers, virtual inspections and more. Cloud-based submissions could be next …
Post-approval change management protocols could go a long way toward smoothing global rollout of analytical method changes, ICH Q12 expert says.
It's another case where the pandemic spurs adoption of ways to speed the manufacture of vaccines and biologics that have been in development for years.